WallStSmart

Crispr Therapeutics AG (CRSP)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Crispr Therapeutics AG generates 453% more annual revenue ($4.10M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. CRSP earns a higher WallStSmart Score of 37/100 (F).

CRSP

Hold

37

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 1/9Altman Z: 2.30

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CRSP2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
68.6%10/10

Revenue surging 68.6% year-over-year

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

CRSP4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-31.3%2/10

ROE of -31.3% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CRSP

The strongest argument for CRSP centers on Revenue Growth, Price/Book. Revenue growth of 68.6% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : CRSP

The primary concerns for CRSP are EPS Growth, Profit Margin, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

CRSP profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

CRSP carries more volatility with a beta of 1.70 — expect wider price swings.

CRSP is growing revenue faster at 68.6% — sustainability is the question.

CRSP generates stronger free cash flow (-109M), providing more financial flexibility.

Bottom Line

CRSP scores higher overall (37/100 vs 24/100) and 68.6% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Crispr Therapeutics AG

HEALTHCARE · BIOTECHNOLOGY · USA

CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?